Core Viewpoint - Southbound funds reduced their holdings in JD Health (06618.HK) by 662,200 shares on November 12, 2025, indicating a slight decrease in investor confidence in the company [1]. Group 1: Shareholding Changes - In the last five trading days, southbound funds increased their holdings on three days, with a total net increase of 656,600 shares [1]. - Over the past 20 trading days, there were 14 days of net increases, totaling 3,399,700 shares [1]. - As of now, southbound funds hold 280 million shares of JD Health, accounting for 8.72% of the company's total issued ordinary shares [1]. Group 2: Trading Data - On November 12, 2025, the total shareholding was 280 million, with a decrease of 662,200 shares, representing a change of -0.24% [2]. - On November 11, 2025, the total shareholding remained at 280 million, with a decrease of 108,500 shares, representing a change of -0.04% [2]. - On November 10, 2025, the total shareholding was 280 million, with an increase of 345,700 shares, representing a change of 0.12% [2]. - On November 7, 2025, the total shareholding was 280 million, with an increase of 475,900 shares, representing a change of 0.17% [2]. - On November 6, 2025, the total shareholding was 279 million, with an increase of 605,600 shares, representing a change of 0.22% [2]. Group 3: Company Overview - JD Health is primarily engaged in providing pharmaceutical and health products, internet medical health services, health management, and intelligent medical health solutions [2]. - The company's business includes retail pharmacy and medical health services, with retail pharmacy operations conducted through self-operated and online platforms as well as instant retail channels [2]. - Medical health services are mainly provided through internet hospitals and medical models, along with online marketing services such as advertising [2].

Investment Rating - The report assigns a "Buy" rating for JD Health (06618) for the first time [2]. Core Insights - JD Health aims to build a comprehensive health management platform centered on pharmaceutical and health product supply, leveraging its supply chain and logistics capabilities to become the largest pharmaceutical retail channel in China [8]. - The opening of online medical insurance purchasing rights is seen as a significant short-term catalyst for the industry, with expectations of increased online drug sales due to policy support [8]. - The company is expected to benefit from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment permissions, with projected revenues of 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025-2027 [8]. Summary by Sections Company Overview - JD Health, established in 2018, is a subsidiary of JD Group focused on healthcare, aiming to create a digital-driven health management platform covering the entire lifecycle of users [11]. - The company has a strong market position, with over 15,000 partnered pharmacies and a presence in more than 490 cities across China [11][29]. Pharmaceutical E-commerce Business - The report highlights the importance of the opening of online medical insurance purchasing rights and the increasing online penetration of pharmaceutical sales as key growth drivers [23]. - JD Health's strategy includes a combination of self-operated, platform-based, and instant retail channels to enhance service capabilities and meet urgent medication needs [26][29]. Financial Forecasts and Valuation - Revenue projections for JD Health are set at 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025, 2026, and 2027, respectively, with adjusted net profits expected to be 5.7 billion, 6.2 billion, and 7.2 billion RMB [34]. - The report anticipates a gradual improvement in gross margins and a decrease in marketing expenses over time, reflecting operational efficiencies [34]. Management and Shareholder Structure - The management team is experienced, with a stable ownership structure, where JD Jiankang Limited holds 67.16% of the shares, controlled by Liu Qiangdong [13][15].

Core Insights - JD Health and Australia's Nature's Way launched a new product aimed at improving youth vision health, named "Vision+", which will be available on JD Health starting November 10 [1][3] - The product is designed for high-intensity users, particularly students, and contains clinically proven ingredients to enhance blue light protection and alleviate eye fatigue [3] Group 1 - The new product "Vision+" focuses on "eye-brain synergy" to improve visual performance [3] - It includes Golden Lute-gen certified lutein and anthocyanins, which target the macula area and enhance blue light protection [3] - The product also contains r-TG DHA and EPA to improve retinal nerve activity and visual signal transmission efficiency [3] Group 2 - The issue of youth vision health is increasingly concerning for Chinese families, making it a focal point for many [3] - JD Health's extensive user base and market insights are seen as strong support for continuous innovation in the youth nutrition health market [3] - Future collaborations between JD Health and Nature's Way will focus on product development and eye health education to bring quality eye care products to more families in China [3]

Group 1 - JD Health (06618.HK) experienced a rise of over 4%, specifically increasing by 4.23% to reach a price of 64.05 HKD [2] - The trading volume for JD Health was reported at 162 million HKD [2]

Core Insights - The domestic AI ecosystem is rapidly improving, with significant acceleration in the AI industry chain, including large models, computing power, and applications [1] - The online consumption ETF fund (159793) is positioned as an AI application ETF and is expected to benefit from the explosion of AI applications [1] Group 1: ETF Performance - As of November 11, 2025, the online consumption ETF fund has seen a cumulative increase of 6.09% over the past three months [1] - The fund's management fee is 0.50%, and the custody fee is 0.10% [1] - The tracking error for the fund over the past month is 0.050% [1] Group 2: Index Composition - The CSI Hong Kong-Shenzhen Online Consumption Theme Index (931481) includes 50 companies involved in online shopping, digital entertainment, online education, and telemedicine [2] - The top ten weighted stocks in the index account for 55.69% of the total index weight, with Alibaba-W (09988) and Tencent Holdings (00700) being the top two [2] Group 3: Stock Performance - The performance of the top ten stocks in the index shows mixed results, with Alibaba-W down 1.68% and Tencent Holdings up 0.92% [3] - JD Health (06618) has increased by 4.15%, while Kuaishou-W (01024) has risen by 1.44% [3]

Core Viewpoint - JD Health (06618) has shown strong performance with a stock increase of over 4%, driven by robust sales growth in pharmaceuticals and health products, indicating a positive outlook for the company [1] Group 1: Financial Performance - JD Health's pharmaceutical sales maintained a year-on-year growth of over 30% in Q3, supported by prescription drugs and chronic disease medications [1] - Health products also sustained a year-on-year growth of over 20%, contributing to an overall revenue increase [1] - The company is expected to achieve a total revenue of 16.6 billion RMB in Q3, reflecting a year-on-year increase of 25% [1] Group 2: Operational Insights - JD Health plans to open 200 new stores in the second half of the year, having opened only 50 stores in Q3 [1] - Adjusted EBIT is projected to rise by over 40% year-on-year to 1.2 billion RMB for Q3 [1] Group 3: Future Outlook - UBS anticipates that the strong revenue growth momentum from the first half of the year will continue into Q3, with sustained growth trends across different product categories [1] - The overall revenue for the second half of the year is expected to increase by 20% year-on-year, with a projected growth rate of 16% for Q4 [1] - The gross margin is expected to improve year-on-year, driven by strong advertising revenue growth and slight expansion in product sales gross margin [1]

Core Viewpoint - JD Health's stock has risen over 4%, driven by strong sales growth in pharmaceuticals and health products, with a projected revenue increase for Q3 [1] Group 1: Financial Performance - JD Health's pharmaceutical sales grew over 30% year-on-year in Q3, supported by prescription drugs and chronic disease medications [1] - Health products maintained a year-on-year growth of over 20%, contributing to an expected total revenue increase of 25% to 16.6 billion RMB for Q3 [1] - Adjusted EBIT is projected to rise over 40% year-on-year to 1.2 billion RMB [1] Group 2: Future Outlook - The company plans to open 200 new stores in the second half of the year, having opened only 50 in Q3 [1] - UBS anticipates that the strong revenue growth momentum from the first half of the year will continue into Q3, with sustained growth across different product categories [1] - The expected revenue growth for the second half of the year is 20%, indicating a 16% increase in Q4 [1]

Core Viewpoint - The Hong Kong stock market is experiencing a positive trend, particularly in the technology and pharmaceutical sectors, with significant interest in Chinese tech stocks due to their unique combination of high growth and high dividend yields [1] Technology Sector Performance - The Hang Seng Index opened higher, with a 0.22% increase to 26,754.93 points, while the Hang Seng Tech Index rose by 0.26% and the Hang Seng China Enterprises Index increased by 0.3% [1] - Notable performers in the tech sector include XPeng Motors, which rose by 2.1%, JD Health with a 1.7% increase, and Trip.com Group, which saw a 1.4% rise [1] - Conversely, NIO experienced a decline of 4.1%, and Alibaba fell by 2.1% [1] Investment Opportunities in AI - Chinese tech stocks are becoming attractive to international capital due to their "high growth + high dividend" advantage amid the accelerating global AI competition [1] - Several foreign institutions highlight that the Chinese AI industry is still in its early development stages, with significant room for growth in computing infrastructure, algorithm innovation, and application implementation [1] Financial Strength of Chinese Tech Leaders - Unlike traditional growth stocks, a number of leading Chinese tech companies are demonstrating robust cash flow and shareholder return capabilities [1] - According to Abbot Investment, many tech firms have dividend yields exceeding 3%, with a payout ratio close to 85%, comparable to levels in the US and European markets [1] - This characteristic of "growth potential alongside dividend income" is particularly valuable in the current low-interest-rate environment [1] AI Industry Chain in Hong Kong - The Hong Kong tech sector is consolidating core domestic AI assets, covering the entire industry chain, including computing power, models, software applications, and hardware terminals [1] - These leading enterprises are becoming pioneers in the revaluation of Chinese assets and are expected to continue benefiting from the accelerated penetration of AI in the future [1] Related ETFs - The Hong Kong Stock Connect Technology ETF (159101) covers the entire technology industry chain [1] - The Hang Seng Internet ETF (513330) focuses on leading internet companies [1]

Core Insights - JD Health collaborates with Nature's Way to launch a new product aimed at improving youth vision health, addressing the growing concern of myopia among Chinese youth [1][2] - The new product, "Vision+", will be available on JD Health starting November 10, leveraging JD's platform to enhance accessibility for families [1] - The partnership has seen significant growth, with a compound annual growth rate exceeding 50% since Nature's Way entered JD's platform in 2016 [2] Industry Context - The prevalence of myopia among individuals under 20 in China is increasing, with over 75% of families prioritizing "eye care nutritional products" in their health expenditures [1] - The product is designed specifically for high-intensity screen users, particularly students facing heavy academic workloads, and contains clinically proven ingredients for eye health [1] - JD Health aims to continue its collaboration with Nature's Way to promote scientific eye care products and enhance public awareness of eye health [2]

Group 1 - The core viewpoint of the report is that Citi has raised its revenue growth forecast for JD Health (06618) for the full year 2025 to 22%, with an expected EBIT margin of 5.7%, up from the previous forecast of 5.0% [1] - The company has also increased its adjusted net profit forecasts for the next two years by 5% and 4% respectively, and raised the target price from HKD 64 to HKD 66, maintaining an "Outperform" rating [1] - JD Health's drug sales in Q3 showed a robust year-on-year growth of over 30%, driven by prescription drugs and chronic disease medications, while health products maintained a year-on-year growth of over 20% [1] Group 2 - The total revenue for JD Health in Q3 is expected to increase by 25% year-on-year to RMB 16.6 billion [1] - The company plans to open 200 stores in the second half of the year, but only opened 50 stores in Q3, leading to an adjusted EBIT expected to rise by over 40% year-on-year to RMB 1.2 billion [1] - For the outlook of the second half of the year, the firm anticipates a year-on-year revenue growth of 20%, indicating a 16% year-on-year increase in Q4 [1]